Kornimate/medical-research-clean huggingface dataset:
magnesium sulphate for treatment of new onset atrial fibrillation in medical intensive care unit patient

Conditions: Atrial Fibrillation

Summary: the purpose of this study is to determine the efficacy of magnesium sulphate for the rate and rhythm control of the new onset (within 48 hours) atrial fibrillation in the hemodynamically unstable patients, admitted in the medical intensive care unit patients.

atrial fibrillation is one of the most common arrhythmia, reported in the hemodynamically unstable patients in the intensive care unit. loss of atrial contraction and the sequential atrioventricular contraction decrease the overall cardiac output which results in severe inadequate tissue perfusion. medications aim for rate and rhythm control are recommended to treat new onset atrial fibrillation. these drugs (verapamil, diltiazem, amiodarone and beta blockers) may further compromise the patients' cardiac output by its' negative inotropic effect. magnesium sulphate with the cell membrane threshold potential stabilizing effect has been reported as an effective drug for rate and rhythm control for post-operative atrial fibrillation and the atrial fibrillation presented in the hospital emergency unit. however, there was inadequate data about the efficacy of magnesium sulphate for treatment of new onset atrial fibrillation in the hemodynamically unstable patients admitted in the medical intensive care unit.

Eligibility criteria:
inclusion criteria: * admitted in medical intensive care unit * age 18 years or more * new onset atrial fibrillation (within 48 hours), persist for at least 1 hour, ventricular rate 120 beats per min or more without evidence of volume depletion (cvp 8 mmhg or more or receive volume resuscitation about 20-30 ml/kg), oxygen saturation not less than 90%, serum potassium level between 3.0-5.0 meq/l, serum calcium level between 8.0-11.0 mg/dl exclusion criteria: * chronic atrial fibrillation * severe valvular heart disease including severe mitral regurgitation, mitral stenosis, aortic regurgitation, aortic stenosis, tricuspid regurgitation, tricuspid stenosis, pulmonic regurgitation or pulmonic stenosis * indicated for electrical cardioversion * severe hypomagnesemia (serum magnesium \< 1.2 mg/dl) * severe hypermagnesemia (serum magnesium \> 5.0 mg/dl) * renal insufficiency with creatinine \> 3.0 mg/dl without renal replacement therapy

Keywords: atrial fibrillation hemodynamically unstable patients magnesium sulfate septic shock medical intensive care unit new onset atrial fibrillation critically ill patients
esmolol pretreatment on pain during injection of propofol

Conditions: Pain

Summary: pain on injection of propofol is a common side effect. the present study was designed to investigate the effect of esmolol on pain on propofol injection and to compare it with remifentanil and placebo.

in a double-blind, prospective trial, 120 patients scheduled to undergo elective surgery were randomized to receive normal saline (n=30), remifentanil 0.35 μg/kg (n=30), esmolol 0.5 mg/kg (n=30), or esmolol 1mg/kg (n=30) as pretreatment. thirty seconds after pretreatment, 25% of the total calculated dose of propofol (2 mg/kg) was administrated into a dorsal hand vein. ten seconds after propofol had been given at the rate of 0.5 ml/sec pain was assessed on a four-point scale (0=none, 1 = mild, 2= moderate, 3= severe).

Eligibility criteria:
inclusion criteria: * patients aged 19-60 years, american society of anesthesiologists (asa) physical status i and ii, scheduled for elective surgery under general anesthesia exclusion criteria: * patients with cardiovascular, neurological or psychiatric disorder problem, patients who received the analgesic or sedative medications within the last 24 hours, and pregnancy were excluded

Keywords: esmolol pain propofol remifentanil
comparison of insulin glargine and nph insulin at night and at hypoglycemia in type 2 diabetes

Conditions: Diabetes

Summary: long-acting insulin injected at bedtime may cause hypoglycemia (low blood sugar) in the night in patients with diabetes. the aims of the study are 1) to compare the dynamic characteristics of long-acting insulin analog glargine with those of nph insulin and placebo during the night and the early morning hours, 2) investigate differences on glucose metabolism of bedtime glargine versus nph insulin at induced hypoglycemia.

patients with advanced type 2 diabetes like those with type 1 diabetes are at risk for defective glucose counterregulation and hypoglycemia unawareness, the components of hypoglycemia-associated autonomic failure and the resultant vicious cycle of recurrent iatrogenic hypoglycemia. this may explain why iatrogenic hypoglycemia becomes limiting to glycemic control as patients approach the insulin-deficient end of the spectrum of type 2 diabetes. compared to neutral protamin hagedorn (nph) insulin glargine is a new long-acting peakless analogue with lower incidence of nocturnal hypoglycemia having the potential to decrease the frequency of hypoglycemia of insulin therapy. modern type 2 diabetes therapy guidelines recommend insulin for an increasing population of patients. there is no doubt that type 2 diabetic patients suffer from hypoglycemia under insulin therapy, however it is not clear whether the extensive studies on hypoglycemia in type 1 patients apply also for type 2 diabetes. recent reports indicate that type 2 diabetic patients of long duration react similarly to a hypoglycemic clamp as type 1 diabetic patients while well controlled type 2 diabetics had even more favorable thresholds for counter-regulatory hormone secretion. on the basis of these considerations the aims of this study are to 1) more precisely define the mechanisms of hypoglycemia in type 2 diabetes, 2) to investigate differences on glucose and lactate metabolism of bedtime nph insulin versus glargine. to address these objectives we will use the hypoglycemic clamping technique combined with infusion of stable isotopes of glucose and lactate and non-invasive measurement of muscle flow characteristics at hypoglycemia.

Eligibility criteria:
inclusion criteria: * type 2 diabetes mellitus * therapy may be with either insulin alone or in combination with oral anti-diabetic agents * metabolic control with hba1c values \< 10% exclusion criteria: * other than type 2 diabetes * pregnancy * systemic corticosteroids, beta-blockers * clinically relevant cardiovascular, gastrointestinal, hepatic, neurologic, endocrine, haematological or other major disease making implementation of the protocol or interpretation of the study results difficult * history of drug or alcohol abuse * impaired renal function (serum creatinine \> 1.3 mg/dl)

Keywords: hypoglycemia, bedtime insulin, long-acting insulin
web-based instrument intervention for individuals with shoulder pain

Conditions: Shoulder Pain; Musculoskeletal Diseases

Summary: introduction: shoulder pain is a condition of high prevalence in the general population. studies indicate that physiotherapeutic treatment with exercise is effective in reducing pain and restoring function in patients with shoulder pain. patients may have difficulty accessing the physiotherapy service due to the cost of treatment, transportation to the service, and long waiting lines. a possible solution is the use of a web-based exercise prescription instrument to increase access to physiotherapy for shoulder pain patients. objective: to verify the effects of an intervention with a web-based instrument compared to a in person and supervised intervention. methods: this study is a controlled, randomized, blinded clinical trial. there will be 184 individuals with shoulder pain who will be randomly assigned to two groups. one group will receive a web-based instrument intervention and the other group will receive the in person and supervised intervention. the intervention will consist of strengthening exercises with emphasis on the lateral rotator and scapulothoracic muscles. the primary outcome will be pain and disability (spadi, shoulder pain and disability index), and the secondary outcomes will be function (dash questionnaire, disabilities of the arm, shoulder and hand), self-efficacy (cpss, chronic pain self-efficacy scale), kinesiophobia (cover scale), patient expectation of treatment (7-point likert scale), and patient satisfaction (global change assessment scale). all outcomes will be measured before and after 12 weeks of treatment (2x/week), after 6 months and 12 months from the end of treatment. normality of data will be verified by kolmogorov smirnov's test. differences between groups will be verified using the mixed linear models with the interaction terms versus time. the effect size will be calculated for the variables between the groups. the significance level will be set at 5%.


Eligibility criteria:
inclusion criteria: * age 18-60; * self-reported pain of intensity equal to or greater than 3 points on the numerical pain scale (ndt) at rest or arm movement in the anterolateral region of the shoulder; * duration of at least 3 months of shoulder pain; * have a mobile phone with android 4.1 or higher. exclusion criteria: * history of trauma related to the onset of symptoms; * history of clavicle, scapula or humerus fracture; * history of surgical stabilization or rotator cuff repair; * history of shoulder dislocation; * pain related to the cervical spine; * adhesive capsulitis; * systemic disease involving the joints and cognitive alteration that makes it impossible to carry out questionnaires or use the mobile application.
a study to assess the efficacy and safety of rel-1017 as adjunctive treatment for major depressive disorder (mdd)

Conditions: Major Depressive Disorder

Summary: this is an outpatient, 2-arm, phase 3, multicenter, randomized, double-blind, placebo-controlled study to assess the efficacy and safety of rel-1017 once daily (qd) as an adjunctive treatment of major depressive disorder. study participants will continue to take their current antidepressant therapy in addition to the study drug or placebo for the duration of the treatment period.


Eligibility criteria:
inclusion criteria: * adults 18 to 65 years, inclusive. * diagnosed with major depressive disorder (mdd) based on structured clinical interview for diagnostic and statistical manual of mental disorders, dsm-5 (scid-5) for mdd. * current major depressive episode. * with inadequate response to 1-3 first-line antidepressants administered at an adequate and stable dose exclusion criteria: * any current and primary psychiatric disorder other than major depressive disorder. * severe alcohol or substance use disorder. * history of bipolar i and ii disorder, psychosis, and/or mania. * acute or chronic condition that, in the investigator's opinion, would limit the subject's ability to complete or participate in this clinical study. * prior participation in a ketamine, esketamine, dextromethorphan or any other nmdar- antagonist study, or received esketamine at any time.

Keywords: rel-1017
g-eye advanced colonoscopy for increased polyp detection rate-randomized tandem study with different endoscopist

Conditions: Colorectal Cancer; Adenoma

Summary: the purpose of this study is to compare the adenoma detection rate of g-eye™ high definition colonoscopy with that of standard high definition colonoscopy.

single center, two-arm, randomized , open-label study with different and blinded endoscopists.

Eligibility criteria:
inclusion criteria: 1. patients over 50 years old 2. referred to colonoscopy for screening, following positive fobt testing, change of bowel habits or for surveillance colonoscopy (history of adenoma resection). 3. the patient must understand and provide written consent for the procedure. exclusion criteria: 1. subjects with inflammatory bowel disease; 2. subjects with a personal history of polyposis syndrome; 3. subjects with suspected chronic stricture potentially precluding complete colonoscopy; 4. subjects with diverticulitis or toxic megacolon; 5. subjects with a history of radiation therapy to abdomen or pelvis; 6. pregnant or lactating female subjects; 7. subjects who are currently enrolled in another clinical investigation. 8. subjects with current oral or parenteral use of anticoagulants 9. subjects with recent (within the last 3 mounts) coronary ischemia or cva (stroke)

Keywords: colorectal cancer adenoma standard colonoscopy g-eye(tm) colonoscopy
direct income support and advice negating spread of epidemic covid-19: a randomized controlled trial

Conditions: COVID-19

Summary: this is a clinical trial of a cash transfer on symptoms consistent with covid-19 and adherence to physical distancing guidance.


Eligibility criteria:
inclusion criteria: * trouble "making ends meet at the end of the month" due to covid-19 related disruptions exclusion criteria: * confirmed positive for covid-19 based on laboratory testing * current symptoms consistent with covid-19
sulforaphane to reduce symptoms of schizophrenia

Conditions: Schizophrenia; Schizoaffective Disorder

Summary: the purpose of this study is to determine if taking a sulforaphane nutraceutical versus a placebo will reduce symptoms of schizophrenia when used in addition to standard antipsychotic medications.


Eligibility criteria:
inclusion criteria: * capacity for written informed consent * age 18-65 years, inclusive * diagnostic and statistical manual of mental disorders, 5th edition (dsm-5) diagnosis of schizophrenia or schizoaffective disorder as determined by the structured clinical interview for dsm-5 disorders (scid-5) * currently an outpatient at time of screening * residual psychotic symptoms of at least moderate severity as evidenced by a positive and negative syndrome scale (panss) total score of 60 or higher and one or more of the following: one or more panss positive symptom scores of 4 or higher; or containing at least three positive or negative items with scores of 3 or higher at the screening visit * receiving antipsychotic medication for at least 8 weeks prior to enrolling in the study with no antipsychotic medication changes within the previous 21 days from visit 2 (week 0) * conformance to port treatment recommendation about maintenance antipsychotic medication dose * proficient in the english language * participated previously in one of our screening studies exclusion criteria: * any clinically significant or unstable medical disorder as determined by the principal investigator and/or the study physician (e.g., hiv infection or other immunodeficiency condition (such as receiving chemotherapy), uncontrolled diabetes, congestive heart failure) * dsm-5 diagnosis of intellectual disability or comparable diagnoses determined by previous versions of the dsm * dsm-5 diagnosis of a moderate or severe substance use disorder, except for caffeine or tobacco, within the last three months prior to the screening visit. if the patient has a positive drug toxicity screen at the time of visit 1 (screening), further evaluation by the investigator will be done of the substance use to determine eligibility. * any current use of a broccoli supplement (e.g., avmacol® or other health food broccoli supplement) * participated in any investigational drug trial in the past 30 days prior to the screening visit * pregnant, planning to become pregnant, or breastfeeding during the study period

Keywords: schizophrenia schizoaffective disorder sulforaphane sulforaphane supplement
effect of hypnotherapy and educational intervention in irritable bowel syndrome

Conditions: Irritable Bowel Syndrome

Summary: aim: gut directed hypnotherapy can reduce ibs symptoms but the mechanisms underlying this therapeutic effect remain unknown. we determined the effect of hypnotherapy and educational intervention on brain responses to cued rectal distensions in ibs patients. methods: 44 women with moderate to severe ibs and 20 healthy controls (hcs) were included.. blood oxygen level dependent (bold) signals were measured by functional magnetic resonance imaging (fmri) during expectation and delivery of high (45 mmhg) and low (15 mmhg) intensity rectal distensions. twenty-five patients were assigned to hypnotherapy (hyp) and 16 to educational intervention (edu). 31 patients completed the treatments and the post treatment fmri. results: similar symptom reduction was achieved in both groups. hyp responders demonstrated a pre-post treatment bold attenuation in both anterior and posterior insula during high intensity distension, while edu responders had a bold attenuation in prefrontal cortex. pre-post differences for the low distension and for the two expectation conditions were almost exclusively seen in the hyp group. for all responders there was a significant correlation between treatment induced reduction of gi related anxiety and bold decrease in the anterior insula. following treatment, the brain response to distension was similar to that observed in hcs, suggesting that the treatment had a normalizing effect on the central processing abnormality of visceral signals in ibs. conclusions: the abnormal processing and enhanced perception of visceral stimuli in ibs can be normalized by psychological interventions. symptom improvement in the treatment groups may be mediated by different brain mechanisms.


Eligibility criteria:
inclusion criteria: rome iii female age 20-60 swedish speaking right-handed exclusion criteria: central acting medication ibd psychiatric diseases abdominal surgery nictoinepacemaker prosthesis metal in the brain claustrophobia large tattoo -
cmap plus trauma-focused cognitive behavior therapy for suicidal ideation among burn survivors

Conditions: Suicidal Ideation; Trauma, Psychological

Summary: the study aims to determine whether cmap plus tfbct is feasible and acceptable for burn survivors with suicidal ideations. to identify any barriers to the recruitment of participants. to determine initial data for the primary outcome measure to perform a sample size calculation for a larger trial.

the study will be conducted in two stages. stage 1 is to adapt the existing cmap intervention for burn survivors and integrate it with existing culturally adapted tfcbt intervention. stage 2 is to test the feasibility and acceptability of study intervention in a randomised controlled trial (rct). in the first stage, the adaptation of the intervention will be carried out by a group of experts including bilingual health experts such as psychiatrists and psychologists, the potential users (i.e., burn survivors with suicidal ideation), and experienced cbt therapists. the expert group will involve in an iterative process of discussion for the adaptation of the intervention including the development of the integrated intervention manual. stage 2 will be a rater blind, two-arm, multi-site, feasibility randomized controlled trial (rct) of cmap plus tf cbt for burn survivors with suicidal ideation randomized either to 1) cmap plus tf cbt added to treatment as usual (tau) or 2) tau alone. a total of n=80 burn survivors with suicidal ideation will be recruited from hospitals (burn injuries units) in karachi, lahore, rawalpindi, quetta, peshawar, multan, and hyderabad, pakistan. each participant in the intervention arm will receive 8 individual sessions of cmap plus tfcbt over 12 weeks. assessment measures will be administered before and after the intervention in the 12th week. all assessments will be rater blind. after post-assessments, a purposefully selected subset (stratified by age \& gender) of participants will be invited for qualitative interviews (upto 15) to explore their experiences and satisfaction with the intervention.

Eligibility criteria:
inclusion criteria: * aged 18 and above * had burn injury and identified for having suicidal ideation measures with beck scale for suicidal ideation (bsi) * able to give informed consent * living within the catchment areas of participating hospitals exclusion criteria: * unable to provide consent due to severe mental or physical illness * unlikely to be available for outcome assessments (temporary residence)
intra-articular lopain (mtx-071) phase i/iia study in chronic osteoarthritic knee joint pain

Conditions: Osteoarthritis, Knee

Summary: phase i/iia study to determine the safety and clinical effects of intra-articular injections of mtx-071 (lopain) in patients with chronic osteoarthritic knee-joint pain.

open label, single-dose, dose-escalating phase i/iia study to determine the safety and clinical effects of intra-articular injections of mtx-071 (lopain) in patients with chronic osteoarthritic knee-joint pain.

Eligibility criteria:
inclusion criteria: * written informed consent * written informed consent * men or women aged between 40 and 70 years * at least 40 mm on motion and at least 10 mm at rest on the 100 mm-vas (visual analog scale) for average arthritic joint pain in the knee to be studied during the last 2 days, with or without pain medication. * previously documented radiography showing a kellgren lawrence grade 2 - 4 severity. * female patients of childbearing potential or female partners of childbearing potential of male patients must agree to use a reliable contraceptive method for at least one month after the injection of mtx-071. * subject is highly likely to comply with the protocol and complete the study. exclusion criteria: * knee surgery within 6 months before study start or planned for any time during the next 6 months. * any injection into the knee to be studied within the preceding 7 days or trauma to the knee not yet healed. * history of any clinically significant cardiac, renal, and/or other relevant disease or malignancy. * history of severe allergic or anaphylactic reactions. * pregnancy. * major bleeding disorder. * clinically significant deviation from the normal laboratory values. * clinically significant abnormal ecg * history of clinically relevant drug/chemical/ substance/alcohol abuse within the past 2 years prior to screening. * symptomatic, viral, bacterial (including upper respiratory infection), or fungal (non-cutaneous) infection within the past 2 weeks prior to study medication administration. * patients positive for human immunodeficiency virus (hiv) antibody, hepatitis c antibody, or for hepatitis b virus surface antigen (hbsag), tuberculosis. * patients who had a corticosteroid injection in the knee to be studied within 3 months prior to baseline or are planned to get a corticosteroid injection within 4 weeks following the injection of mtx-071. * vaccination within 60 days prior to study medication administration. * systemic immunosuppressant agent within 6 months prior to study medication administration * experimental agent within 30 days or ten half-lives, whichever is longer, prior to study medication administration. * any other condition, which in the opinion of the investigator, precludes the subject's participation in the trial. * patients who are dependent on the sponsor or investigator.
clinical outcomes of implantationof black diaphragm intraocular lens in complete aniridia and aphakia due to posttraumatic eye rupture

Conditions: Aphakia Due to Trauma; Eye; Rupture, Traumatic, With Loss of Intraocular Tissue; Aniridia

Summary: purpose: to assess long-term outcomes of implantation of black diaphragmintraocular lens (bd iol) in postraumatic aniridia and aphakia due to eye rupture. methods: this is retrospective consecutive case series of 14 eyes with post-traumatic complete aniridia and aphakia treated withscleral fixation of bd iol with. measurements included ophthalmological comorbidities, best corrected visual acuity (bcva), complications, and postoperative interventions. the average postoperative follow-up period was 36 months.


Eligibility criteria:
inclusion criteria: post-traumatic complete aniridia and aphakia exclusion criteria: active ocluar inflammation or infection

Keywords: aphakia black diaphragmintraocular lens eye rupture aniridia